Pharnext to Attend January Investor Conferences
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA) , a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that senior management will be attending the following conferences taking place in January in France:
- Oddo 20 th Midcap Forum on January 5-6 in Lyon Convention Center
- Invest Securities BioMed Event – 2nd Edition - on January 26 in Salons Hoche, Paris
If you are interested in meeting the Pharnext management team during either of these events, please send an email to firstname.lastname@example.org .
Senior management will also be available for meetings in the U.S. in San Francisco, CA from January 9-13 during the 35th Annual J.P. Morgan Healthcare Conference . If you are interested in meeting the Pharnext management team, please send an email to Sarah McCabe at email@example.com .
Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY© . The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG© might offer several key advantages: efficacy, safety, and robust intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
PLEODRUG© and PLEOTHERAPY© are registered trademarks by Pharnext
Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
Investors Relations (Europe)
Julie Coulot, +33 (0)1 44 71 20 40
Investors Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe, +1-212-362-1200
Media Relations (Europe)
+33 (0)1 44 54 36 64
Media Relations (U.S.)
Tony Russo, Ph.D., +1-212-845-4251
Matt Middleman, M.D., +1-212-845-4272
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
NV-RIMINI-STREET,-INC.24.5.2018 01:04 | pressemeddelelse
Rimini Street Delivers Premium SAP Support to Solar Frontier
NY-CORSEARCH24.5.2018 00:13 | pressemeddelelse
Corsearch Announces Strategic Partnerships with Key-Systems GmbH and INCOPRO
CQN-ZEBRA-MEDICAL-VISION23.5.2018 23:32 | pressemeddelelse
CORRECTING and REPLACING Zebra Medical Vision Announces CE Approval of its Seventh AI Imaging Algorithm - Mammography Lesion Detection
SEOUL-SEMICONDUCTOR23.5.2018 20:42 | pressemeddelelse
Seoul Semiconductor AC LED Modules Pass 4kV Surge Testing
GCEL/INSME23.5.2018 20:36 | pressemeddelelse
GCEL Releases G20 Nations Case Study Involving 90 Ministries, NGOs & IGOs Defining the Guidelines for the Digital Economy Era
LTI23.5.2018 17:06 | pressemeddelelse
LTI Q4 USD Revenue Growth up 5.3% QoQ and 21.6% YoY; FY18 Revenues of USD1.13bn, up 16.7%; Digital Revenues Grow 42% in FY18
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum